remains largely unknown. Consequently, the current study sought to define whether TFEB influences endothelial cell (EC) function and regulates postischemic angiogenesis. In the present work, utilizing genetically engineered EC-specific TFEB transgenic mice, we found that TFEB functions as a positive regulator of angiogenesis with capability to modulate EC migration, tube formation, and apoptosis and improve postischemic blood flow recovery. Mechanistically, TFEB activates AMPK (AMP-activated protein kinase)-α signaling and upregulates autophagy. Our findings uncovered a novel direct link between TFEB and postischemic angiogenesis and established a unique feedforward loop between TFEB and AMPKα.
Methods
An expanded Methods section is available in the Online Data Supplement.
The data that support the findings of this study are available from the corresponding author on reasonable request. Microarray data have been submitted to the NCBI (The National Center for Biotechnology Information) Gene Expression Omnibus database in MIAME (minimum information about a microarray experiment) format.
Results

TFEB Is Upregulated in Ischemic Skeletal Muscle
In response to ischemia, a cluster of antiangiogenic and proangiogenic genes are dynamically downregulated or upregulated in mice. 20 Autophagy as a critical cellular process may also be involved in the postischemic tissue regeneration. To determine whether TFEB-an autophagy master gene-is responsive to ischemia, we analyzed the expression of TFEB in the ischemic skeletal muscle at day 3 after ischemia. TFEB was upregulated to an average of 3.1-fold and 3-fold at the mRNA and protein levels, respectively, when compared with sham control (Online Figure IA and IB). To further validate the expression of TFEB in ECs, we performed immunostaining for TFEB and CD31-a specific marker of mature EC. As shown in Online Figure IC , TFEB fluorescence intensity was stronger in the ischemic microenvironment in vivo, and CD31-positive cells expressed higher TFEB protein. Nutrition depletion is a major component of ischemia in vivo. Of note, under normal growth conditions, TFEB was localized in the lysosome, but it translocated to the nucleus in serum-free medium ( Figure 1A and 1B). LAMP1 (lysosomal-associated membrane protein 1) was used as a lysosome marker. Interestingly, we observed increased TFEB translocation from the lysosomes to the nucleus in ECs on VEGF (vascular endothelial growth factor) stimulation ( Figure 1C and 1D ). VEGF treatment also increased TFEB protein expression in a rapid manner, even as short as 15 minutes after VEGF treatment ( Figure 1E and 1F). Taken together, our data suggest that TFEB is a nutrient-and proangiogenic factor-responsive transcription factor and, consequently, may play a role in the adaptation to the complicated ischemic microenvironmental conditions.
Increased Angiogenesis and Improved Blood Flow Recovery in EC-TFEB Transgenic Mice After Ischemic Injury
To determine the role of endothelial TFEB in angiogenesis in vivo, we generated an EC-specific TFEB transgenic (EC-TFEB Tg) mouse expressing the human TFEB transgene from a mouse Tie2 (endothelial-specific receptor tyrosine kinase) promoter. The genotyping of transgenic mice (Online Figure  IIA) , detection of TFEB transgene expression in both isolated mouse aortic ECs in vitro (Online Figure IIB) and aortic ECs in vivo (Online Figure IIC) 
Novelty and Significance
What Is Known?
• TFEB (transcription factor EB) is a lysosome biogenesis and autophagy master gene that modulates cell and tissue function. TFEB-deficient mouse is embryonic lethal with impaired placental vascularization.
• Autophagy is crucial in maintaining vessel wall homeostasis, and autophagic dysregulation may induce vascular pathological process.
• AMPK (AMP-activated protein kinase)-α is a key metabolic sensor and critical in regulation of autophagy and angiogenesis in endothelial cells.
What New Information Does This Article Contribute?
• TFEB is upregulated in ischemic conditions in endothelial cells.
• Endothelial TFEB promotes postischemic angiogenesis and improves blood flow recovery.
• Autophagy and AMPKα signaling mediate the proangiogenic effect of TFEB in endothelial cells.
• MCOLN1 (mucolipin-1) is critical for TFEB-dependent proangiogenic effect.
Postischemic angiogenesis is critical for tissue regeneration and blood flow recovery. Through gain-and loss-of-function strategies in vivo, we found that endothelial TFEB promotes angiogenesis after hindlimb ischemia and thus confers a beneficial effect on blood flow recovery in postischemic conditions. Mechanistically, TFEB activates AMPKα and enhances autophagy, which mediates the TFEB-dependent regulation of angiogenesis. These findings expand our knowledge on the role of endothelial TFEB to maintain vascular homeostasis and define TFEB as a potential therapeutic target for treatment of ischemic vascular disease.
(Online Figure IID through IIG). No significant difference in capillary density was found in the gastrocnemius muscle between normal control mice and EC-TFEB Tg mice (Online Figure IIH and III) in basal conditions (before hindlimb ischemia), ruling out that the transgenic mice might have higher baseline capillary density. To reveal the effect of TFEB on ischemic angiogenesis, EC-TFEB Tg and control mice were subjected to hindlimb ischemia by ligation of the femoral artery. Using Laser Doppler perfusion imaging technology, we observed that the blood perfusion was significantly improved in EC-TFEB Tg mice at days 7, 14, 21, and 28 after ischemic injury compared with control mice (Figure 2A) , with no appreciable differences at day 3 ( Figure 2B ). The necrotic degree reflected by necrotic toe number was considerably less in EC-TFEB Tg mice than that in control mice at day 14 after artery ligation with 12.5% of animals with 5 necrotic toes in the control mice and 12.5% showing no necrotic toes in the EC-TFEB Tg mice ( Figure 2C ). Consistent with these results, the capillary density in skeletal muscle at day 14 after ischemic injury was an average of 1.44-fold higher in EC-TFEB Tg mice when compared with control mice ( Figure 2D and 2E). To determine whether TFEB affects arteriogenesis under ischemic conditions, we performed microcomputed tomography as described previously [21] [22] [23] at 14 days after hindlimb ischemia in EC-TFEB Tg and control mice. The EC-TFEB Tg mice showed no significant difference in vascular volume, vessel number, and vascular volume to vessel number ratio in the ischemic thigh when compared with control mice (Online Figure III) .
Decreased Angiogenesis and Attenuated Blood Flow Recovery in EC-TFEB KO Mice After Ischemic Injury
We further determined the role of endothelial TFEB in angiogenesis in EC-TFEB KO (knockout; floxed-TFEB homozygous/ VE-Cad Cre+) mice. The TFEB deficiency in the EC-TFEB KO mice was validated by genotyping (Online Figure IVA and IVB) and detection of TFEB expression in both isolated mouse aortic ECs in vitro (Online Figure IVC) and aortic ECs in vivo . Twenty hours later, the cells were cultured in 10% fetal bovine serum (FBS) DMEM (control) or serum-free (SF) DMEM for 5 h. The subcellular location of TFEB was determined by GFP fluorescence. LAMP1 (lysosomal-associated membrane protein 1) staining was used as marker of lysosomes. Representative images are shown in (A) and quantitatively analyzed in (B; scale bar=50 μm). C and D, TFEB translocation induced by VEGF (vascular endothelial growth factor). HCAECs (human coronary artery endothelial cells) were infected with Ad-TFEB-EGFP (10 MOI). Twenty hours later, the cells were treated with VEGF (10 ng/mL) or no treatment (control) in 10% FBS DMEM for 4 h. Representative images of TFEB-EGFP fluorescence and LAMP1 immunofluorescence are shown in (C), and TFEB nuclear translocation was quantitatively analyzed in (D; scale bar=50 μm). E and F, VEGF induces TFEB protein expression. Under normal growth medium, HCAECs were stimulated with VEGF (10 ng/mL) for the indicated time. The expression of TFEB was detected by Western blot (E). Band intensity of TFEB was quantitatively analyzed and normalized against GAPDH (F). Three independent experiments were performed in all cases, and data are presented as mean±SEM. **P<0.01. GFP indicates green fluorescent protein.
(Online Figure IVD) . No obvious histological changes were observed in the thoracic aorta and mesenteric artery in the EC-TFEB KO mice when compared with the control mice (Online Figure IVE through IVH). In the hindlimb ischemic model, blood perfusion was significantly attenuated in EC-TFEB mice at days 14, 21, and 28 after ischemic injury compared with control mice ( Figure 3A) , with no appreciable differences at day 3 ( Figure 3B ). The EC-TFEB KO mice exhibited more severe toe necrotic score with 25% of animals having 5 necrotic toes compared with control mice in which 12.5% had 5 necrotic toes ( Figure 3C ). The capillary density in skeletal muscle at day 14 after ischemic injury was an average of 0.68-fold lower in EC-TFEB KO mice when compared with control mice ( Figure 3D and 3E). Similarly, we further performed microcomputed tomography to assess arteriogeneis in EC-TFEB KO mice at 14 days after hindlimb ischemia. The EC-TFEB KO mice showed no significant difference in arteriogenesis (Online Figure V) . Collectively, our data indicate that endothelial TFEB plays a critical role in postischemic angiogenesis.
TFEB Promotes Endothelial Tube Formation and Migration
EC proliferation, migration, and tube formation are critical processes for angiogenesis, in which the formation of capillary-like tubes by ECs is a crucial step for blood flow recovery in vivo. We assessed the contribution of TFEB to EC biological functions by gain-and loss-offunction approaches. Adenovirus-mediated overexpression of TFEB was assessed by Western blot ( Figure 4A ). Endothelial cell (EC)-specific TFEB (transcription factor EB) transgene improves blood flow recovery after ischemic injury. EC-TFEB transgenic (Tg) and control mice were subjected to hindlimb ischemia. A, Representative images showing blood flow reperfusion monitored by Doppler laser ultrasound at the indicated time after ischemic injury. B, The ratio of ischemic/nonischemic perfusion was quantitatively analyzed at the indicated time points (n=8 for each group). C, Necrotic toe score was determined at day 14 after ischemic injury (n=8 for each group). D, Representative images showing CD31 immunostaining in gastrocnemius muscle at 2 wk after artery ligation (scale bar=50 μm). E, The capillary density was evaluated as the ratio of capillary number per muscle fiber number (n=5 for each group). Data are presented as mean±SEM. *P<0.05, **P<0.01.
TFEB overexpression significantly promotes EC migration ( Figure 4B ). Tube formation assay showed that TFEB significantly increased tube number and branching points to an average of 270% and 184%, respectively ( Figure 4C and 4D). The knockdown efficiency of TFEB in ECs was determined by Western blot ( Figure 4E ). Consistent with the gain-of-function study, siRNA-mediated TFEB knockdown significantly inhibited EC migration ( Figure 4F ) and reduced the tube number and branching points by an average of 79.7% and 61.4%, respectively, compared with siRNA-control ( Figure 4G and 4H). Moreover, TFEB has an inhibitory effect on EC apoptosis. Caspase 3 and PARP (poly [ADP-ribose] polymerase) cleavage were reduced by TFEB overexpression (Online Figure VIA and VIB) and consistently enhanced by TFEB knockdown in the staurosporine-treated ECs (Online Figure VIC and VID). TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) staining showed that the EC-TFEB transgene attenuated cell apoptosis (Online Figure  VIIA) , and consistently, EC-TFEB deficiency enhanced apoptosis in ischemic gastrocnemius muscle and the small arteries in ischemic skeletal muscle (Online Figure VIIB) . However, TFEB overexpression did not significantly affect EC proliferation as measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Online Figure  VIIIA) and BrdU (bromodeoxyuridine) incorporation assays (Online Figure VIIIB) . Taken together, our findings indicate that TFEB regulates EC biological functions essential for angiogenesis, including enhanced migration and tube formation and inhibition of apoptosis. Endothelial cell (EC)-specific TFEB (transcription factor EB) KO (knockout) attenuates blood flow recovery after ischemic injury. EC-TFEB KO and control mice were subjected to hindlimb ischemia. A, Representative images of Doppler laser ultrasound showing blood flow reperfusion monitored at the indicated time after artery injury. B, The ratio of ischemic/nonischemic perfusion was quantitatively analyzed at the indicated time points (n=8 for each group). C, Necrotic toe score was determined at day 14 after ischemic injury (n=8 for each group). D, Representative images showing CD31 immunostaining in gastrocnemius muscle 2 wk after artery ligation (scale bar=50 μm). E, The capillary density was evaluated as the ratio of capillary number per muscle fiber number (n=5 for each group). Data are presented as mean±SEM. *P<0.05, **P<0.01.
TFEB Regulates Autophagy in ECs
Next, we addressed the molecular mechanism that mediates the proangiogenic effect of TFEB in ECs. TFEB, as an autophagy master regulator, upregulates autophagy and lysosome biogenesis in various cell types. 9 Our microarray analysis suggests that TFEB upregulates numerous autophagy-related genes (Online Figure IXA) . TFEB overexpression significantly increased the expression of autophagy genes, such as MCOLN1 (mucolipin-1) and ATG9B (autophagyrelated protein 9B), at the mRNA level ( Figure 5A ). LC3-II (microtubule-associated protein 1 light chain 3 alpha)/LC3-I ratio was significantly increased in the TFEB-overexpressing ECs and consistently decreased in the TFEB-deficient ECs ( Figure 5B and 5C). The mouse aortic ring sprouting assay is widely used to quantify the development of microvessels and assess salient steps in angiogenesis. 24 This ex vivo study suggests that EC-TFEB deficiency significantly decreases the aortic ring sprouting ( Figure 5D ), which reinforces the results that EC-TFEB KO impairs postischemic angiogenesis in vivo. Consistently, the EC-TFEB transgene increased the aortic ring sprouting ( Figure 5E ). We applied bafilomycin A-an autophagy inhibitor-to assess the contribution of autophagy to TFEB-induced aortic sprouting. Inhibition of autophagy significantly attenuated the proangiogenic effect of TFEB ( Figure 5E ). AMPKα is a well-recognized key regulator of autophagy, 25 angiogenesis, 26 and energy homeostasis. We observed that inhibition of AMPKα by antagonist compound C decreased aortic ring sprouting. In the presence of compound C, TFEB upregulation cannot induce sprout outgrowth ( Figure 5E ), suggesting that AMPKα is critical for TFEB-regulated proangiogenic effect. Our microarray data also revealed that TFEB regulates angiogenesis-related genes (Online Figure IXB) .
Autophagy and AMPKα Are Required for TFEB to Regulate Tube Formation
Besides the finding that autophagy mediates the effect of TFEB on aortic ring sprouting, we demonstrated that 3-methyladenine (3-MA)-an autophagy antagonist that inhibits class III PI3K (phosphatidylinositol 3-kinase)-attenuates the positive effect of TFEB on tube formation ( Figure 6A ). To determine whether AMPKα signaling is essential to mediate TFEB effects on tube formation, we antagonized AMPKα activity by either pharmacological inactivation or siRNA-mediated knockdown. TFEB overexpression failed to increase tube formation when compared with GFP (green fluorescent protein) control in the presence of compound C ( Figure 6B ). In the AMPKα-knockdown cells, there was no significant difference in both tube number and branching points between TFEB and GFP groups ( Figure 6C ), even on 80% downregulation in AMPKα protein levels ( Figure 6D) . Moreover, the proangiogenic capacity of the TFEB transgene was significantly attenuated in the Matrigel plugs containing compound C or 3-methyladenine (Online Figure X) . AMPKα activates autophagy through inhibition of mTOR (mammalian target of rapamycin) signaling pathway. 25, 28 We determined the phosphorylation of mTOR downstream effectors, 4E-BP1 (eukaryotic translation initiation factor 4E-binding protein 1) and S6 ribosomal protein. The phosphorylation of both proteins was significantly attenuated in the TFEB-overexpressing ECs (Online Figure XI) . Taken together, our findings suggest that AMPKα and autophagy are critical signaling pathways mediating the TFEB proangiogenic effects in ECs. 
TFEB Activates the AMPKα Signaling Pathway
Next, we demonstrated that the AMPKα signaling pathway was enhanced by TFEB in ECs. Phosphorylation of AMPKα at Thr172 and ACC (acetyl-CoA carboxylase)-a downstream substrate of AMPKα-at Ser79 was significantly increased by TFEB overexpression in the presence of VEGF. At 5 minutes after VEGF stimulation, the phosphorylation of AMPKα at Thr172 was increased by 1.96-fold and ACC at Ser79 was up by 1.72-fold ( Figure 7A and 7B ). In the absence of VEGF, TFEB could increase AMPKα activation at a dose of ≥20 MOI (multiplicity of infection; Online Figure  XIIA and XIIB). Consistently, TFEB knockdown decreased phosphorylation of both proteins both under basal conditions and on VEGF activation ( Figure 7C and 7D) . Furthermore, we isolated mouse aortic ECs from control and EC-TFEB Tg mice. The phosphorylation of AMPKα was enhanced in the EC-TFEB Tg ECs (Online Figure XIIC and XIID) , in agreement with the in vitro data observed in primary human ECs. Next, we set to understand how TFEB activates AMPKα. AMPKα is activated by multiple well-recognized regulators, such as LKB1 (serine/threonine kinase 11) and CAMKKβ (Ca 2+ /calmodulin-dependent protein kinase kinase-β). 26 However, our data showed that the phosphorylation of LKB1 at Ser428 was not significantly changed by TFEB, implying that LKB1 may not a mediator in the TFEB-dependent effects on AMPKα (Online Figure XIII) .
We used STO-609 (5 μmol/L)-a CAMKKβ inhibitor-to antagonize the CAMKKβ activity. Enhanced phosphorylation of AMPKα by TFEB overexpression was significantly attenuated in the presence of STO-609 ( Figure 7E and 7F) . We further inactivated CAMKKβ by siRNA and observed a similar phenotype in the CAMKKβ-knockdown ECs ( Figure 7G and 7H) . Collectively, our data suggest that CAMKKβ mediates the TFEB-dependent modulation of AMPKα signaling.
MCOLN1 Mediates the Proangiogenic Effect of TFEB in ECs
As a transcription factor, translocation of TFEB to the nucleus could result in transcriptional regulation of its target genes. 9, 29, 30 MCOLN1, also known as TRPML1 (transient receptor potential mucolipin 1) or ML1, is an endosomal and lysosomal calcium channel. TFEB increased the expression of MCOLN1 to an average of 3.3-fold at the mRNA level (Online Figure  XIVA) . Furthermore, we demonstrated that TFEB bound to the MCOLN1 promoter as determined by ChIP (chromatin immunoprecipitation) assay (Online Figure XIVB) . TFEB overexpression induced an average of 2.98-fold increase in its binding to the MCOLN1 promoter. A previous study demonstrated that TFEB elevated the intracellular calcium concentration in HeLa cells-an immortal human cervical cancer cell line. 31 We found that TFEB could significantly increase the intracellular 
Ca
2+ in ECs as well, which may contribute to the activation of CAMKKβ by TFEB (Online Figure XIVC and XIVD) . In MCOLN1 knockdown ECs (Figure 8A ), the TFEB-induced elevation of intracellular calcium (Online Figure XIVC and XIVD), AMPKα activation ( Figure 8B and 8C) , and tube formation ( Figure 8D) were significantly attenuated. These data indicate that MCOLN1 is critical in the TFEB-dependent proangiogenic phenotype.
Discussion
Although TFEB has been demonstrated to be a pivotal regulator of autophagy and lysosome biogenesis, the role of TFEB in vascular biology remains largely unknown. Our previous study demonstrated that TFEB inhibits EC inflammation and reduces atherosclerosis in mice. 17 TFEB global KO mice are embryonic lethal with impaired vascularization, 19 but the availability and viability of EC-selective TFEB KO and Tie2-driven TFEB transgenic mice provided valuable tools to investigate its specific function in ECs. Here, using these EC-specific genetically engineered transgenic mice, we identified TFEB as a novel factor promoting angiogenesis, which defines TFEB as a potential therapeutic target relevant to the treatment of ischemic vascular disease.
The patterns of gene expression after acute hindlimb ischemia revealed that proangiogenic factors, such as VEGF, PlGF (placental growth factor), HDGF (heparin-binding . Twenty-four hours later, the cells were treated with VEGF (vascular endothelial growth factor; 10 ng/mL) for the indicated time. C and D, HUVECs were transfected with si-TFEB or si-Ct (20 nmol/L) for 3 d, and then treated with VEGF (10 ng/mL) for the indicated time. Phosphorylated and total AMPKα and ACC (acetyl-CoA carboxylase) were detected by Western blot (A and C). Three independent experiments were performed. Band intensities of phosphorylated AMPKα and ACC were quantitatively analyzed and normalized against total AMPKα or ACC, respectively (B and D). E and F, HUVECs were infected with Ad-GFP or Ad-TFEB (10 MOI). Forty-eight hours later, the cells were pretreated with STO-609 (5 μmol/L) for 30 min, and then stimulated with VEGF (10 ng/mL) for the indicated time. G and H, HUVECs were transfected with si-CAMKKβ (Ca 2+ /calmodulin-dependent protein kinase kinase-β; 20 nmol/L) or si-Ct. Twenty-four hours later, the cells were infected with Ad-GFP or Ad-TFEB for 48 h followed by VEGF (10 ng/mL) stimulation. Phosphorylated and total AMPKα were detected by Western blot (E and G). Three independent experiments were performed. The band intensity of phosphorylated AMPKα was quantitatively analyzed and normalized against total AMPKα (F and H) . In all cases, data are presented as mean±SEM. *P<0.05, **P<0.01. GFP indicates green fluorescent protein; and NS, nonsignificant. growth factor), and MCP1 (monocyte chemoattractant protein 1), were upregulated at early stages of ischemia (3-7 days). 20, 32 We found that TFEB was increased in the ischemic skeletal muscle at day 3 after vascular injury in vivo, and TFEB subcellular localization was responsive to nutrient deprivation in vitro. The elevated expression or nuclear translocation of TFEB in response to ischemia or nutrient deprivation implies an adaptive and potentially protective effect of TFEB on ECs. TFEB can be phosphorylated by mTOR and retained at the lysosome membrane. 10, 29, 30 However, in response to adverse environmental cues, TFEB is dephosphorylated and translocates to the nucleus to transcriptionally regulate gene expression of its targets. 10, 29, 30 Consistent with these data, we found that TFEB clearly accumulated in the nucleus ( Figure 1A ) in response to serum deprivation. Consequently, it is possible that TFEB could mediate mTOR-dependent signal transduction under conditions of starvation in ECs. On the other hand, TFEB suppressed mTOR activity in ECs (Online Figure XI) , revealing an interplay between TFEB and mTOR signaling. As a novel finding, we observed that TFEB is responsive to VEGF in ECs, which expands our insight in the molecular regulation of TFEB, including gene expression and nuclear translocation. Inhibition of VEGFR2 (VEGF receptor 2) or AMPKα prevented decorin-induced TFEB upregulation and nuclear translocation in ECs. 33 Follow-up studies are warranted to determine whether VEGFR2 and AMPKα mediate the VEGF-dependent regulation of TFEB in ECs.
Compared with the regulation of angiogenesis in response to ischemia, the control of arteriogenesis in general and collateral formation in particular remains unclear at large. 34 Arteriogenesis can occur at sites of arterial occlusion where ischemia is not prominent, but hemodynamic factors, such as shear stress forces, are changed. 35 Our data suggest that neither EC-TFEB transgene nor EC-TFEB KO have appreciable effects on arteriogenesis in the ischemic thigh as assessed by microcomputed tomography (Online Figures III and IV) . We investigated the entire plethora of biological features of EC function, such as proliferation, migration, apoptosis, and other signal transduction pathways, potentially involved in the proangiogenic phenotype elicited by increased TFEB expression. Our data suggest that tube formation, migration, and survival are key processes by which TFEB critically modulates angiogenesis-a conclusion supported by our in vivo data. Indeed, a growing number of studies suggest that TFEB can inhibit apoptosis in various cell types and tissues. Hepatic TFEB gene transfer decreased detrimental activation of liver apoptosis in the AATD (α-1 antitrypsin deficient) mice 36 and MSD (multiple sulfatase deficient) mice. 31 TFEB had a robust protective effect and enhanced cell survival in midbrain dopamine neurons 12 and cardiomyctes. 15, 16 Mechanistically, TFEB activates AMPKα and autophagy in ECs. TFEB is a master gene that regulates autophagy and lysosome biogenesis. 10, 11, 29, 30 Autophagy is crucial in maintaining vessel wall homeostasis, and autophagic dysregulation may induce vascular aging and associated pathological process. Autophagy may protect ECs from glucose, angiotensin II, and oxygen-glucose deprivation-induced endothelial dysfunction. 37 Accumulated studies indicate that proper autophagy promotes EC tube formation and migration in vitro [38] [39] [40] [41] [42] and angiogenesis in vivo, 42 depending on the cellular and molecular microenvironment. A recent study demonstrated that endothelial-specific deletion of raptor (an essential component of the mTORC1 signaling complex) protects against hindlimb ischemia in diabetic mice via activation of autophagy. 43 In the current study, we systematically addressed the critical role of TFEB in postischemic restoration and biological processes in ECs and revealed an essential role of autophagy in TFEB-induced tube formation, aortic sprouting, and angiogenesis. Although our data suggest that AMPKα and autophagy mediate the effect of TFEB on angiogenesis, we cannot exclude the potential mediator role of other proangiogenic factors in the TFEB regulation of angiogenesis.
AMPKα is a critical regulator for autophagy 25 and angiogenesis under hypoxia. 26 Through inhibition of AMPKα in tube formation assay in vitro (Figure 4 ), aortic ring sprouting assay ex vivo ( Figure 5 ), and Matrigel plug in vivo (Online Figure X) , we determined that AMPKα is a novel signaling pathway that mediates the proangiogenic effect of TFEB in ECs. It has been demonstrated that AMPKα inhibits mTOR signaling. 25, 28 One of our major findings in the current study is that TFEB activates AMPKα and simultaneously inhibits mTOR signaling in ECs (Online Figure XI) , suggesting a TFEB-AMPKα-mTOR axis in ECs, which probably further contributes to lower level of phosphorylated TFEB (higher transcriptional activity). Thus, TFEB and AMPKα may form a positive feedback loop in ECs ( Figure 8E ). Indeed, besides regulating autophagy, AMPKα is a multifunctional kinase affecting metabolism and cytoskeletal signaling 28 that may also mediate autophagy-independent positive effects on angiogenesis. Whether AMPKα can further promote angiogenesis in an autophagy-independent fashion in the context of TFEB upregulation is still unclear and warrants follow-up studies.
In our experimental system, we observed that TFEB did not alter the LKB1 phosphorylation-an important upstream regulator of AMPKα. 27 However, we demonstrated that CAMKKβ is required for the TFEB-dependent regulation of AMPKα. It has been reported that CAMKKβ was critical for VEGF to activate AMPKα. 44 Recent molecular studies of endolysosomal Ca 2+ physiology revealed that Ca 2+ is critical in controlling diverse cellular processes and diseases. 45 MCOLN1 plays a critical role in calcium homeostasis and could control the intracellular Ca 2+ concentration. 31 In our study, we demonstrated that TFEB upregulates MCOLN1 and increases intracellular Ca . Lysosomal Ca 2+ activates calcinuerin, which induces TFEB nuclear translocation by binding and dephosphorylating TFEB. 46 Thus, a self-sustaining positive feedback loop between TFEB and calcium signaling may exist as well in ECs. In the current study, our data suggest that autophagy and AMPKα activation are, at the least, required for TFEB to regulate tube formation. Yet, we must acknowledge that TFEB may also cross talk with other angiogenic signaling pathways and may regulate angiogenesis under other specific conditions, such as development, diabetes mellitus, and tumor formation, which remain to be investigated. Interestingly, our data suggest that TFEB is required for angiogenesis and for activation of autophagy even in basal conditions in vitro, thus opening the possibility that TFEB is a homeostatic regulator of angiogenesis in the absence of EC dysfunction.
The limitation of our study is the unavailability of ECspecific inactivation of AMPKα in our EC-TFEB mouse models. Pharmacological inhibition of AMPKα in vivo may introduce confounding factors from systemic effects on other tissues and complicate the interpretation of the data and elucidation of the mechanism. 27 EC-TFEB KO/EC-ATG5 (autophagy-related 5) KO and EC-TFEB KO/EC-AMPKα KO mice would be ideal tools to determine the mediating role of autophagy and AMPKα, respectively, in TFEB regulation of angiogenesis in vivo. Another limitation is that Tie2 and VECad-driven Cre recombinase are expressed, albeit at low levels, in blood monocytes and bone marrow-derived hematopoietic cells, 47, 48 respectively. However, our previous study demonstrated that TFEB protein abundance was not significantly increased in peritoneal or bone marrow-derived macrophages from EC-TFEB Tg mice. 17 In conclusion, we provide evidence that TFEB is critical for angiogenesis and, consequently, for improving blood flow reperfusion under ischemic conditions. Based on our findings, we uncovered a molecular mechanism underlying the positive effect of TFEB on angiogenesis. Our findings have relevance for the treatment of chronic ischemia and define TFEB as a new potential therapeutic target for ischemic vascular injury. Understanding how to best exploit this novel molecular target could contribute to therapeutic strategies aimed at rescuing ischemic tissues at large.
